EVIDENCE VS HYPE · VITAMIN D & RESPIRATORY INFECTIONS
The hype: Taking vitamin D strengthens your immune system so you catch fewer colds.
Vitamin D has genuine biological roles, and earlier research suggested a small reduction in respiratory infections. That makes the claim plausible. But biological plausibility, a favourable blood test and fewer actual illnesses are different kinds of evidence. Newer trials have made the prevention story less certain.
The short answer
Vitamin D should be used where appropriate to prevent or correct deficiency. It is not established as a reliable way for everyone to prevent colds or other acute respiratory infections. A large updated 2025 meta-analysis found no statistically significant overall protection. A small effect remains possible, but the evidence does not justify promising that supplements will stop you getting ill.
Why people believe it
Winter combines more respiratory illness with less opportunity for skin production of vitamin D in the UK. Vitamin D also participates in immune biology. Those observations explain why researchers investigated supplementation; they do not establish that low vitamin D causes every winter infection or that a pill removes the other risks.
People who take supplements may differ from people who do not in age, health, habits or access to care. Likewise, illness itself may alter time outdoors and nutrition. A trial asking whether random assignment to vitamin D changes infection frequency is more informative than comparing the vitamin D levels of healthy and unwell people.
What the evidence says
Earlier pooled research suggested modest protection
A 2021 systematic review found a small statistically significant reduction in the odds of acute respiratory infection. Its primary analysis of 37 trials gave an odds ratio of 0.92, with a confidence interval of 0.86–0.99. This was not an eight-percentage-point reduction in an individual's risk, and it was far from proof of universal protection. Trial populations and regimens varied. Read the 2021 review ↗
The result was nevertheless reasonable grounds for continued research. Evidence can change without earlier researchers having acted in bad faith: estimates become more precise or move as larger studies test the same question.
The updated review did not establish an overall benefit
The 2025 update's primary vitamin D versus placebo comparison included 40 studies and 61,589 participants. The pooled odds ratio was 0.94, with a 95% confidence interval of 0.88–1.00 and a p value of 0.057. The authors concluded that statistically significant overall protection was not demonstrated. Pre-specified analyses did not establish that the effect differed by baseline vitamin D status, age, dosing frequency or dose. Funnel-plot asymmetry also raised concern about the distribution of available studies. The review reported no external funding; some authors disclosed support outside the submitted work. Read the updated review and its linked correction record ↗
A result close to the conventional significance threshold is not a switch between “works” and “never works”. The estimate remains compatible with a small benefit. Equally, it does not support advertising supplementation as a proven dependable preventive treatment. Subgroups need credible comparisons between groups, not simply a significant result in one subgroup and a non-significant result in another.
A practical UK trial did not find fewer infections
CORONAVIT randomly assigned 6,200 UK participants aged at least 16 to an offer of vitamin D testing with lower-dose or higher-dose supplementation if their result was below the trial threshold, or to no offer. The regimens were 800 or 3,200 IU daily, and follow-up lasted six months. This open-label test-and-treat strategy did not reduce confirmed acute respiratory infections or COVID-19. Read CORONAVIT ↗
It was not a blinded pill-versus-placebo experiment, and it tested a programme rather than just the molecule. Outside supplement use and changing infection exposure can complicate such trials. Its practical design nonetheless matters: a population offer of testing and supplements did not deliver the promised infection prevention in that setting.
The limitations
“Respiratory infection” can mean different outcomes across studies: self-reported symptoms, clinician-confirmed illness, an infection requiring treatment or a particular virus. Fewer minor symptoms would not automatically demonstrate fewer hospital admissions. Studies of prevention also cannot establish that vitamin D treats an infection once it has started.
Trials differ in season, follow-up, background intake and adherence. Large intermittent doses are not interchangeable with daily dosing. Although researchers continue to investigate potentially responsive groups, selecting a favourable subgroup after reviewing results can generate a hypothesis rather than a reliable prescription.
People with clinically important deficiency still need appropriate care. A prevention review cannot answer every treatment question for a severely deficient patient. On the other hand, deficiency should not be assumed merely because someone catches frequent colds; many other explanations are possible.
What this means for you
Follow vitamin D prevention advice for its intended purpose, rather than expecting an immunity shield. In the UK, the NHS advises consideration of a 10-microgram daily supplement in autumn and winter, with year-round advice for some at-risk groups. This is not an infection-treatment dose. NHS guidance ↗
Do not increase the dose to compensate for every cold, or treat supplements as a substitute for recommended vaccination, appropriate infection precautions or medical assessment when needed. A product marketed as “immune support” may describe an accepted nutrient function without demonstrating that its users experience fewer infections.
If you are prescribed vitamin D, keep following the prescription unless your clinician changes it. If you are choosing a supplement, check the actual daily amount and avoid stacking multiple products. Discuss suitability if you have relevant medical conditions or take medicines affecting calcium or vitamin D metabolism.
For the strongest established purpose, see our investigation of vitamin D, deficiency and bone health. The Vitamin D3 Evidence Hub separates that purpose from mood, formulation and higher-dose claims.
Research & Sources
- Jolliffe et al. (2021): respiratory-infection systematic review.
- Jolliffe et al. (2025): updated review, with correction linked in the record.
- Jolliffe et al. (2022): CORONAVIT trial.
- NHS: appropriate supplementation and safety.
Review information
Evidence reviewed: October 2026. Indexed reports and guidance were checked; abstracts are not presented as full-text assessments. Educational information, not a diagnosis or treatment plan. No product testing or commercial endorsement was performed. Research conclusions are independent of optional buying guidance. Affiliate disclosure · Editorial methodology.